Application Note: Profiling EZH2 Inhibitors with the Transzyme HMT EZH2 Assay Kit
13 March 2014

Numerous studies have shown that histone methyltransferase (HMT) EZH2 is overexpressed in prostate, breast, bladder, brain, and other tumor types and inhibitors of the enzyme recently began clinical testing as anti-cancer drugs. This application note describes how compounds can be rapidly profiled for potency as HMT EZH2 inhibitors using the Transzyme HMT EZH2 Assay kit.